Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.

NCT05242042 is registered in ClinicalTrials.gov with Shanghai JunTop Biosciences Co., LTD as lead sponsor.

NCT NCT05242042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05242042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
Lead sponsor
Shanghai JunTop Biosciences Co., LTD
Phase
Phase 2/3
Overall status
Terminated
Start date
January 28, 2022
Completion date
March 23, 2023
Enrollment
381 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate covid-19